

Diagnosis and management of adrenal insufficiency

Bancos, Irina; Hahner, Stefanie; Tomlinson, Jeremy; Arlt, Wiebke

DOI:

10.1016/S2213-8587(14)70142-1

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

Document Version Peer reviewed version

Citation for published version (Harvard):

Bancos, I, Hahner, S, Tomlinson, J & Arlt, W 2015, 'Diagnosis and management of adrenal insufficiency', The Lancet Diabetes and Endocrinology, vol. 3, no. 3, pp. 216-26. https://doi.org/10.1016/S2213-8587(14)70142-1

Link to publication on Research at Birmingham portal

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes

- •Users may freely distribute the URL that is used to identify this publication.
- •Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
 •User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- •Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 03. May. 2024

Table 1. Causes of adrenal insufficiency according to underlying pathogenesis. Most frequent causes of primary adrenal insufficiency are autoimmune adrenalitis and congenital adrenal hyperplasia; secondary adrenal insufficiency is most frequently the result of hypothalamic-pituitary tumours and their treatment.

Cause	Primary adrenal insufficiency	Secondary adrenal insufficiency
Autoimmune	 Can occur in isolation or as part of autoimmune polyglandular syndromes (APS) Isolated Addison's disease (30-40% of patients with autoimmune adrenalitis) APS type 1 (5-10%; also termed APECED OMIM 240300): caused by <i>AIRE</i> gene mutations. Adrenal insufficiency in combination with other endocrine (hypoparathyroidism (76-93%), premature ovarian failure (17-50%), type 1 diabetes mellitus (2-12%)) and non-endocrine autoimmune disease (mucocutaneous candidiasis (73-100%), alopecia (29-37%), vitiligo (8-15%), coeliac disease (15-22%), pernicious anaemia (13-15%), autoimmune hepatitis (12-20%), Sjogren Syndrome (12%) and ectodermal dystrophy (dental enamel hypoplasia) (77-82%)) APS type 2 (60%): adrenal insufficiency in combination with other endocrine autoimmune disease (hypo- or hyperthyroidism (60%), premature ovarian failure (7-21%), 	Lymphocytic hypophysitis – rare, may occur in relation to pregnancy. Can present as panhypopituitarism or isolated ACTH deficiency, the latter sometimes in combination with primary autoimmune-mediated hypothyroidism)

	type 1 diabetes mellitus (1-15%), pernicious anaemia (5-	
	12%), vitiligo (6-14%), coeliac disease (1-4%), alopecia (2-	
	6%))	
Compression /	Bilateral adrenal metastasis (mostly originating from solid organ	Pituitary macroadenomas (pituitary carcinoma very rare);
replacement of	tumours such as lung, breast, colon cancer)	craniopharyngioma; meningioma; ependymoma; intra- and
normal tissue		suprasellar metastases (mostly lung, breast, colon cancer)
Infection	Tuberculosis; HIV; CMV; fungal infections	Tuberculosis; histoplasmosis; actinomycosis
Hemorrhage /	Thrombocytopenia; Waterhouse-Friderichsen syndrome; trauma;	Pituitary apoplexy (mostly in the setting of a pituitary
necrosis	lupus erythematosus; antiphospholipid syndrome, panarteritis	macroadenoma); Sheehan syndrome due to transient
/thrombosis	nodosa; treatment with anticoagulants; treatment with tyrosine	hypocirculation and subsequent necrosis of the pituitary
	kinase inhibitors	(e.g. due to significant blood loss)
Infiltration	Sarcoidosis, amyloidosis, haemochromatosis, histiocytosis,	Wegener's granulomatosis, sarcoidosis, amyloidosis,
	lymphoma	haemochromatosis, lymphoma
Surgery/	Bilateral adrenalectomy	Treatment of hypothalamic-pituitary tumours by surgery
Trauma		and/or radiation; traumatic brain injury
Monogenic	Congenital adrenal hyperplasia (CAH) variants:	Combined pituitary hormone deficiency (CPHD) variants:
causes of	- 21-hydroxylase deficiency (21OHD) (OMIM #201910) (most common cause of disease; >95% of CAH cases)	CPHD2 (OMIM #262600) CPHD3 (OMIM #221750)
adrenal	- 11β-hydroxylase deficiency (11OHD) (OMIM #610613)	CPHD4 (OMIM #262700)
	- P450 oxidoreductase deficiency (PORD) (OMIM #613571)	CPHD5 (OMIM #182230)
insufficiency	- 3β-hydroxysteroid dehydrogenase type 2 (3β-HSD2)	CPHD6 (OMIM #613986)
	deficiency (OMIM #613890);	
	- 17α- hydroxylase deficiency (17OHD) (OMIM #202110)	Isolated ACTH deficiency due to mutations in TBX19 (OMIM #201400);
	X-linked adrenoleukodystrophy (ALD) or	

	adrenomyeloneuropathy (AMN) (OMIM #300100) APS type 1 (=APECED) (OMIM #240300) For very rare inborn causes of primary adrenal insufficiency including congenital lipoid adrenal hyperplasia, congenital adrenal hypoplasia and familial glucocorticoid deficiency see Supplemental Table 1.	For more details on the above and even rarer inborn causes of secondary adrenal insufficiency see Supplemental Table 2.	
Drugs interfering	 Increased metabolism of glucocorticoids: concomitant use reduces corticosteroid levels Inducers of CYP3A4 (resulting in increased inactivation of cortisol by 6β-hydroxylation) - mitotane, phenytoin, rifampicin, troglitazone, phenobarbital 		
with adrenal function	 Impaired glucocorticoid action: peripheral glucocorticoid insensitivity Glucocorticoid receptor antagonist - mifepristone (RU486) Suppression of glucocorticoid-induced gene transcription - chlorpromazine, imipramine 		
	 Suppression of hypothalamic-pituitary-adrenal axis: Down-regulation of endogenous ACTH release: chronic exogenous glucocorticoid administration (including topical, inhaled, oral, intra-articular or parenteral administration), megestrol acetate, medroxyprogesterone acetate, cyproterone acetate, opiates 		
	 Inhibition of steroidogenic enzymes involved in cortisol production Inhibition of mitochondrial (type 1) cytochrome P450 enzymes (CYP11A1, CYP11B1/2): ketoconazole, fluconazole, itraconazole, etomidate, metyrapone, aminoglutethimide Inhibition of 3β-HSD2: trilostane 		
	Adrenal haemorrhage • Anticoagulants: heparin, warfarin		
	Autoimmune hypohysitis: • Anti-CTLA4 antibody: ipilimumab		

Table 2: Measures for prevention of adrenal crisis

Action point	Intervention	
Identify and define the	Steroid emergency card (check that available and up to date)	
problem	 Medical alert bracelet or necklace: "Adrenal insufficiency – needs steroids!" 	
Educate patient (and partner/parents)	- Sick day full 1. Need to double the foutilite oat glucocorticold dose when the patient experiences level	
	Sick day rule 2 : Need to inject a glucocorticoid preparation intra-muscularly or intravenously in case of severe illness, trauma, persistent vomiting, when fasting for a procedure (colonoscopy!) or during surgical intervention.	
	Special attention to:	
	• Explaining the rationale for dose adjustment in stress / sickness	
	Discussing the situations requiring dose adjustment	
	Discussing symptoms and signs of emergency adrenal crisis	
	Teaching parenteral self-administration of glucocorticoid preparation	
	Enforce the need to go to hospital after emergency injection	
Provide patient with	 Sufficient supply of hydrocortisone and fludrocortisone (accounting for possible sick days) Hydrocortisone emergency injection kit prescription (vials of 100 mg hydrocortisone sodium such as Solu-Cortef, syringes, needles; alternatively also hydrocortisone or prednisolone suppositories) Leaflet with information on adrenal crisis and hospitalization to be shown to health care staff, clearly advise regarding the need to inject 100 mg hydrocortisone immediately i.v. or i.m., followed by continuous infusion of 200 mg/24 hrs Emergency phone number of endocrine specialist team 	
Follow up	Re-enforce education and confirm understanding during each follow up visit (at least annually in a patient without specific problems or recent crises, otherwise more frequently)	